Roche Holding AG
🇨🇭Switzerland
- Country
- 🇨🇭Switzerland
- Ownership
- Public
- Established
- 1896-01-15
- Employees
- 103.6K
- Market Cap
- $270.5B
- Website
- http://www.roche.com
A Study of RO4917838 (Bitopertin) in Patients With Sub-optimally Controlled Symptoms of Schizophrenia (WN25305)
Phase 3
Completed
- Conditions
- Schizophrenia
- Interventions
- First Posted Date
- 2010-11-05
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 604
- Registration Number
- NCT01235559
A Study of RoActemra/Actemra (Tocilizumab) in Combination With Methotrexate in Patients With Active Rheumatoid Arthritis Who Have an Inadequate Response to Disease-Modifying Antirheumatic Drugs (DMARDs) (ALABASTER)
Phase 3
Completed
- Conditions
- Rheumatoid Arthritis
- Interventions
- First Posted Date
- 2010-11-05
- Last Posted Date
- 2014-11-07
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 71
- Registration Number
- NCT01235507
A Study of RO4917838 (Bitopertin) in Patients With Acute Exacerbation of Schizophrenia
Phase 2
Completed
- Conditions
- Schizophrenia
- Interventions
- First Posted Date
- 2010-11-04
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 301
- Registration Number
- NCT01234779
A Study of RoActemra/Actemra (Tocilizumab) Given Subcutaneously in Combination With Traditional DMARDs in Patients With Moderate to Severe Active Rheumatoid Arthritis
- First Posted Date
- 2010-11-02
- Last Posted Date
- 2015-07-29
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 656
- Registration Number
- NCT01232569
A Study of Tarceva (Erlotinib) in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer Following 4 Cycles of Platinum-based Chemotherapy Without Disease Progression
- First Posted Date
- 2010-10-29
- Last Posted Date
- 2015-03-30
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 51
- Registration Number
- NCT01230710
A Study of Avastin (Bevacizumab) Plus Xeloda (Capecitabine) in Patients With Locally Advanced Rectal Cancer.
Phase 2
Completed
- Conditions
- Colorectal Cancer
- Interventions
- Drug: bevacizumab [Avastin]Drug: capecitabine [Xeloda]Radiation: Radiation therapyProcedure: Mesorectal excisionDrug: 5-fluorouracilDrug: leucovorin
- First Posted Date
- 2010-10-25
- Last Posted Date
- 2015-08-17
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 43
- Registration Number
- NCT01227707
An Observational Study on the Safety Profile of MabThera/Rituxan (Rituximab) in Combination With Chemotherapy in Patients With B Cell-lineage Chronic Lymphocytic Leukaemia (MABERYC)
Completed
- Conditions
- Lymphocytic Leukemia, Chronic
- Interventions
- Drug: ChemotherapyDrug: rituximab [MabThera/Rituxan]
- First Posted Date
- 2010-10-19
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 219
- Registration Number
- NCT01224093
A Study of Gantenerumab in Participants With Prodromal Alzheimer's Disease
- First Posted Date
- 2010-10-19
- Last Posted Date
- 2021-12-13
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 799
- Registration Number
- NCT01224106
- Locations
- 🇺🇸
Butler Hospital, Providence, Rhode Island, United States
🇧🇷Hospital Mae de Deus, Porto Alegre, RS, Brazil
🇩🇰Rigshospitalet, Hukommelsesklinikken, Koebenhavn Oe, Denmark
An Observational Study of Herceptin (Trastuzumab) in Patients With HER2-positive Advanced Gastric Cancer
Completed
- Conditions
- Gastric Cancer
- First Posted Date
- 2010-10-14
- Last Posted Date
- 2018-06-20
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 443
- Registration Number
- NCT01220934
- Locations
- 🇩🇪
Krankenhaus Nordwest; Klinik f. Onkologie und Hämatologie, Frankfurt, Germany
A Study of Danoprevir Boosted With Low Dose Ritonavir in Combination With Pegasys and Copegus in Treatment-Naive Patients With Chronic Hepatitis C Virus Infection
Phase 2
Completed
- Conditions
- Hepatitis C, Chronic
- Interventions
- First Posted Date
- 2010-10-14
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 421
- Registration Number
- NCT01220947
© Copyright 2025. All Rights Reserved by MedPath